Pfizer broke ground in late June of 2016 on the $350 million Global Biotechnology Center in China. Located in the Hangzhou Economic Development Area (HEDA), the facility will manufacture pharmaceutical biosimilars, which are drugs designed with similar active properties to existing licensed therapies. The project will feature a modular production facility created by GE Healthcare that utilizes flexible, single-use biomanufacturing technologies. The duration of construction will be 18 months with completion expected in early 2018. Utilization of GE’s KUBio system will significantly accelerate the delivery of the project as well as meeting international standards for quality, safety, efficiency, and sustainability.